Rhythm Pharmaceuticals Inc (RYTM)
52.98
+3.98
(+8.11%)
USD |
NASDAQ |
Nov 04, 16:00
52.98
0.00 (0.00%)
After-Hours: 20:00
Rhythm Pharmaceuticals Enterprise Value: 2.817B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 2.817B |
| October 31, 2024 | 2.739B |
| October 30, 2024 | 2.850B |
| October 29, 2024 | 2.850B |
| October 28, 2024 | 2.843B |
| October 25, 2024 | 2.789B |
| October 24, 2024 | 2.860B |
| October 23, 2024 | 2.818B |
| October 22, 2024 | 2.825B |
| October 21, 2024 | 2.889B |
| October 18, 2024 | 2.930B |
| October 17, 2024 | 2.941B |
| October 16, 2024 | 3.020B |
| October 15, 2024 | 2.903B |
| October 14, 2024 | 2.892B |
| October 11, 2024 | 2.867B |
| October 10, 2024 | 2.754B |
| October 09, 2024 | 2.738B |
| October 08, 2024 | 2.761B |
| October 07, 2024 | 2.707B |
| October 04, 2024 | 2.855B |
| October 03, 2024 | 2.791B |
| October 02, 2024 | 2.939B |
| October 01, 2024 | 2.986B |
| September 30, 2024 | 3.024B |
| Date | Value |
|---|---|
| September 27, 2024 | 2.960B |
| September 26, 2024 | 2.947B |
| September 25, 2024 | 3.015B |
| September 24, 2024 | 2.954B |
| September 23, 2024 | 2.943B |
| September 20, 2024 | 3.049B |
| September 19, 2024 | 3.156B |
| September 18, 2024 | 3.100B |
| September 17, 2024 | 3.072B |
| September 16, 2024 | 2.848B |
| September 13, 2024 | 2.854B |
| September 12, 2024 | 2.836B |
| September 11, 2024 | 2.836B |
| September 10, 2024 | 2.822B |
| September 09, 2024 | 2.918B |
| September 06, 2024 | 2.832B |
| September 05, 2024 | 2.772B |
| September 04, 2024 | 2.688B |
| September 03, 2024 | 2.630B |
| August 30, 2024 | 2.712B |
| August 29, 2024 | 2.639B |
| August 28, 2024 | 2.657B |
| August 27, 2024 | 2.721B |
| August 26, 2024 | 2.878B |
| August 23, 2024 | 2.641B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.74M
Minimum
May 19 2022
3.156B
Maximum
Sep 19 2024
1.035B
Average
813.17M
Median
Nov 19 2019
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| TG Therapeutics Inc | 4.050B |
| Regeneron Pharmaceuticals Inc | 84.89B |
| Mirum Pharmaceuticals Inc | 1.956B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.26M |
| Revenue (Quarterly) | 29.08M |
| Total Expenses (Quarterly) | 69.56M |
| EPS Diluted (Quarterly) | -0.55 |
| Gross Profit Margin (Quarterly) | 89.87% |
| Profit Margin (Quarterly) | -110.9% |
| Earnings Yield | -8.23% |
| Normalized Earnings Yield | -8.446 |